Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21622095rdf:typepubmed:Citationlld:pubmed
pubmed-article:21622095lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:21622095lifeskim:mentionsumls-concept:C1427643lld:lifeskim
pubmed-article:21622095lifeskim:mentionsumls-concept:C0086982lld:lifeskim
pubmed-article:21622095lifeskim:mentionsumls-concept:C1515877lld:lifeskim
pubmed-article:21622095lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:21622095lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:21622095lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:21622095pubmed:dateCreated2011-5-30lld:pubmed
pubmed-article:21622095pubmed:abstractTextPirh2 is an E3 ligase that negatively regulates p53 through both direct physical interaction and ubiquitin-mediated proteolysis. Here, we identified a novel Pirh2-interacting protein, AIG1, by yeast two-hybrid screening and confirmed its interaction with p53 both in vitro and in vivo. Quantitative real-time reverse transcription-PCR analysis showed that AIG1 expression levels were reduced in 50 out of 79 (63%) human hepatocellular carcinomas (HCCs) when compared to matched, non-cancerous liver tissue; levels were significantly different between HCCs with or without lymph node metastasis. Kaplan-Meier analysis indicated that the survival time of HCC patients down-regulated for AIG1 is much shorter than it is for patients up-regulated for AIG1 expression (p = 0.0313 as determined by the Log-rank test). Finally, AIG1 activated the nuclear factor of activated T cells (NFAT) signaling pathway in a dose-dependent manner when over-expressed in HEK293T cells. Our results suggest AIG1 could serve as a new biomarker for the diagnosis and prognostic evaluation of HCCs.lld:pubmed
pubmed-article:21622095pubmed:languageenglld:pubmed
pubmed-article:21622095pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21622095pubmed:citationSubsetIMlld:pubmed
pubmed-article:21622095pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21622095pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21622095pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21622095pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21622095pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21622095pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21622095pubmed:statusMEDLINElld:pubmed
pubmed-article:21622095pubmed:issn1945-0508lld:pubmed
pubmed-article:21622095pubmed:authorpubmed-author:ZhangWeiWlld:pubmed
pubmed-article:21622095pubmed:authorpubmed-author:WuGangGlld:pubmed
pubmed-article:21622095pubmed:authorpubmed-author:HuoKekeKlld:pubmed
pubmed-article:21622095pubmed:authorpubmed-author:SunMeiqianMlld:pubmed
pubmed-article:21622095pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21622095pubmed:volume3lld:pubmed
pubmed-article:21622095pubmed:ownerNLMlld:pubmed
pubmed-article:21622095pubmed:authorsCompleteYlld:pubmed
pubmed-article:21622095pubmed:pagination834-42lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:meshHeadingpubmed-meshheading:21622095...lld:pubmed
pubmed-article:21622095pubmed:year2011lld:pubmed
pubmed-article:21622095pubmed:articleTitleAIG1 is a novel Pirh2-interacting protein that activates the NFAT signaling pathway.lld:pubmed
pubmed-article:21622095pubmed:affiliationState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, PR China.lld:pubmed
pubmed-article:21622095pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21622095pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:25898entrezgene:pubmedpubmed-article:21622095lld:entrezgene
entrez-gene:51390entrezgene:pubmedpubmed-article:21622095lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21622095lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21622095lld:entrezgene